Dossier · Private startup · 0 independent sources
MDClone
Last updated: Jul 31, 2026
MDClone develops ADAMS, a healthcare data exploration and collaboration platform that combines longitudinal clinical-data infrastructure, governed self-service analytics, synthetic data, and privacy controls. It is aimed at helping health systems and life-sciences organizations investigate real-world data, share insights, and turn findings into operational or research action without broadly distributing source records.
Visit WebsiteCompany Overview
MDClone's core product is the ADAMS Platform and its associated ADAMS Center operating model. The platform organizes healthcare information longitudinally and is designed to ingest or connect structured and unstructured data, continuous feeds, and source-system data into a healthcare-specific environment. Its workflow is organized around asking questions, discovering cohorts, acting on findings, measuring outcomes, and sharing governed results. This is a meaningful distinction from a conventional dashboard product: the intended user includes a clinician, researcher, quality leader, or operational manager who needs to investigate an unexpected pattern without first turning the question into a bespoke data-engineering project. ADAMS Copilot adds a generative-AI interface for data preparation, statistical analysis assistance, visualization, and data-mining exploration. That feature increases accessibility, but its reliability depends on permissions, data quality, human review, and the underlying platform rather than on a chatbot alone.
The commercial problem is well defined. Hospitals, payers, and life-sciences companies hold fragmented clinical, financial, genomic, utilization, and operational information, but access is slowed by incompatible schemas, privacy obligations, scarce analysts, and a separation between data teams and frontline decision-makers. MDClone positions ADAMS for clinical and operational improvement, retrospective research, real-world evidence, health economics and outcomes work, clinical-trial site selection, patient-recruitment analysis, and controlled collaboration between providers and external organizations. Its Connect-oriented offering emphasizes an invited environment for third parties to explore data, while synthetic-data capabilities are intended to reduce the need to expose identifiable patient records. These are credible enterprise use cases, although the record should not treat synthetic data as automatically anonymous or suitable for every clinical or regulatory decision.
Public company materials identify customers or collaborations including Washington University School of Medicine, Intermountain Healthcare, the VHA Innovation Ecosystem, the National Institutes of Health, the Ottawa Hospital, Regenstrief Institute, Sheba Medical Center, and University Hospital Basel. MDClone also reports a footprint of more than 20 sites and more than 50 million unique patient records across the United States, Canada, and Israel, and its website describes service to the Israeli healthcare market. Those figures and customer references are company-reported traction signals, not audited revenue, retention, outcomes, or proof that every named institution uses the full platform. The March 2022 company announcement of a $63 million Series C led by Warburg Pincus and Viola Growth, with existing investors participating, supports a substantial private financing history. The main commercialization diligence questions are recurring software revenue, deployment duration, implementation and services intensity, expansion within accounts, renewal rates, data-rights structure, and the degree to which outcomes are independently measured.
The competitive field spans healthcare real-world-data and analytics vendors, synthetic-data specialists, privacy-preserving data-sharing platforms, cloud data stacks, and internal health-system teams. MDClone's most credible edge is the combination of a healthcare-native longitudinal data model, clinician-oriented dynamic exploration, synthetic privacy, and collaboration workflows in one product. Domain-specific workflows and accumulated implementation knowledge can create switching costs, but the moat is not proven to be purely algorithmic: customers can assemble parts of the stack with Datavant, Aetion, Palantir Foundry, Tonic.ai, Mostly AI, Hazy, cloud-native lakehouse tools, or bespoke analytics teams. Defense and national-security relevance is plausible but not demonstrated as a core market. The same privacy-preserving analytics could support military or veteran health systems, readiness medicine, epidemiology, and sensitive medical-AI development; the public record reviewed here does not establish a defense contract, classified deployment, or battlefield application. Strategic assessment should therefore treat defense health as an option value and diligence hypothesis, not current traction.
Dual-Use Assessment
MDClone has substantive but indirect dual-use potential: governed healthcare analytics, synthetic data, and privacy-preserving collaboration could be useful to military or veteran health systems, readiness medicine, epidemiology, and sensitive medical-AI programs. Public materials establish healthcare, VHA, and NIH-related customer references, but do not establish a defense procurement, classified work, or operational military deployment; the score therefore reflects adjacency rather than demonstrated defense revenue.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
MDClone remains a credible internal priority signal for a dual-use and deep-tech database because it addresses a persistent bottleneck in regulated data: organizations need analytical access and collaboration while limiting exposure of patient records. The Series C, named health-system and public-sector references, international expansion, and continued ADAMS product development support a real commercial platform rather than an unvalidated concept. This is not an investment recommendation. Before assigning greater priority, diligence should test recurring software revenue, gross margin, implementation burden, customer concentration, retention and expansion, synthetic-data fidelity and leakage testing, privacy and security controls, Copilot evaluation, and the proportion of value delivered by software versus services. Defense relevance should be validated separately rather than inferred from healthcare customers alone.
Strategic Value to U.S.-Israel Alliance
MDClone can make sensitive healthcare data more usable across clinical, research, operational, and external-collaboration workflows while preserving governance boundaries. That is strategically relevant to healthcare modernization, public-sector health analytics, and medical-AI development. A military or veteran-health deployment could extend the value proposition to readiness and population health, but it remains an unconfirmed adjacency; strategic value should not be overstated as defense capability without evidence of security accreditation, procurement, or mission outcomes.
Key Technologies
- Longitudinal healthcare data lake and temporal data model
- Synthetic data generation and synthetic privacy controls
- Governed self-service cohort discovery and dynamic exploration
- Structured and unstructured clinical-data integration
- Semantic and ontology harmonization across source systems
- Continuous data feeds and third-party analytics integration
- Generative-AI research and statistical-analysis assistance in ADAMS Copilot
Use Cases & Applications
- Clinical cohort discovery and retrospective research
- Hospital quality, utilization, and care-pathway improvement
- Real-world evidence and health economics and outcomes research
- Clinical-trial site selection and patient-recruitment analysis
- Privacy-preserving collaboration between health systems and life-sciences organizations
- Healthcare AI and machine-learning development with controlled data access
- Cross-institution exploration without distributing raw patient records
- Potential military or veteran health readiness and population-health analytics, subject to procurement and security validation
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 11 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- mdclone.com Public source used for profile verification.
- LinkedIn company page Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.